Clinical trials: Cannabis Use Disorder, Severe
Cannabis Use Disorder, Moderate, Cannabis Use Disorder, Severe
Tirzepatide in the Treatment of Cannabis Use Disorder
Cannabis is the most commonly used psychoactive substance in Canada. A sub-group of cannabis users develop Cannabis Use Disorder (CUD).
- Trial name
- NCT07671248
- Testing
- Tirzepatide
- Where
- Canada
- Volunteers
- 15 people
- Sponsor
- McMaster University
Cannabis Use Disorder, Anxiety
Use of a Generative AI (Gen-AI) Chatbot for Anxiety and Depression Among Persons With Cannabis Use
The goal of this clinical trial is to learn if Therabot-CALM (Cannabis, Anxiety, Low Mood) has acceptability among users and could work to improve the symptoms of persons with cannabis use disorder and anxiety and/or depression.
- Conditions
- Cannabis Use Disorder, Anxiety, Depression, Anxiety, Depression - Major Depressive Disorder
- Trial name
- NCT06920238
- Testing
- Therabot-CALM
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Trustees of Dartmouth College
Cannabis Use Disorder, Severe
Cannabis and Processing Emotions Study
The goal of this study is to test a causal neural mechanism of cannabis use-related problem recognition in individuals with severe cannabis use disorder using a non-invasive form of neuromodulation called transcranial magnetic…
- Trial name
- CAPE (NCT06907979)
- Testing
- TMS - Active iTBS, TMS - Active cTBS
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Auburn University
Cannabis Use Disorder, Moderate, Cannabis Use Disorder, Severe
Brain Exercise and Addiction Trial
Heavy cannabis use is associated with substantive learning and memory impairments and elevated risk of psychopathology. It has been repeatedly demonstrated that the hippocampus, centrally implicated in these processes, is…
- Trial name
- BEAT (NCT04902092)
- Testing
- High Intensity Interval Training, Strength and Resistance Training
- Where
- Australia
- Volunteers
- 65 people
- Sponsor
- Monash University
Mental Illness, Schizophrenia
Genetic Counselling in the Prevention of Mental Health Consequences of Cannabis Use
Severe mental illness (SMI) refers to the most burdensome psychiatric conditions. The need to pre-empt the onset of SMI is pressing because once SMI develops, quality of life is poor and available treatments have limited…
- Conditions
- Mental Illness, Schizophrenia, Bipolar Disorder, Major Depressive Disorder
- Trial name
- IMAGINE (NCT03601026)
- Testing
- Genetic counselling
- Where
- Canada
- Volunteers
- 120 people
- Sponsor
- Nova Scotia Health Authority
Cannabis Use Disorder, Severe
Impact of Cannabis Use and Abstinence on Emotion
The goal of this experimental study is to test how three weeks of cannabis abstinence impacts threat and reward processing in females with Cannabis Use Disorder.
- Trial name
- ICAE (NCT07746440)
- Testing
- Contingency management for cannabis abstinence and lab visit attendance, Contingency management for lab visit attendance
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Florida State University
Cannabis Use Disorder, Mild, Cannabis Use Disorder, Moderate
Gender/Sex & CUD Remission
Adults (ages 18+) who would like to reduce their cannabis use (N=224) will be enrolled in an 8-week treatment program. All participants will receive counseling (1 goals session with a therapist followed by 7 weekly computerized…
- Conditions
- Cannabis Use Disorder, Mild, Cannabis Use Disorder, Moderate, Cannabis Use Disorder, Severe
- Trial name
- NCT04964739
- Testing
- Cognitive Behavioral Therapy (CBT4CBT)
- Where
- United States
- Volunteers
- 224 people
- Sponsor
- Medical University of South Carolina
Cannabis Use Disorder, Mild, Cannabis Use Disorder, Moderate
Cannabis Use Disorder Treatment Study
The purpose of this study is to test a text-delivered counseling program to stop or reduce cannabis use among young adults (ages 18 to 25).
- Conditions
- Cannabis Use Disorder, Mild, Cannabis Use Disorder, Moderate, Cannabis Use Disorder, Severe
- Trial name
- NCT04567394
- Testing
- Peer Network Counseling-txt
- Where
- 2 sites in United States
- Volunteers
- 1,077 people
- Sponsor
- The University of Tennessee, Knoxville
Psychotic Disorders, Cannabis Use Disorder
Avatar Intervention for the Treatment of Cannabis Use Disorder in Patients With Severe Mental Health Disorders
This is a proof-of-concept of a new Virtual Reality (VR) Avatar Intervention for Cannabis Use Disorders (CUD) in patients with psychotic disorders and/or mood disorders.
- Conditions
- Psychotic Disorders, Cannabis Use Disorder, Mental Health Disorder
- Trial name
- Avatar-CUD (NCT05726617)
- Testing
- Avatar Intervention
- Where
- Canada
- Volunteers
- 32 people
- Sponsor
- Ciusss de L'Est de l'Île de Montréal
Bipolar Disorder, Cannabis Use
Gabapentin for Restoring GABA/Glutamate Homeostasis in Co-occurring Bipolar and Cannabis Use Disorders
This research study evaluates the effects of an FDA-approved medication Gabapentin in individuals with Bipolar Disorder who smoke marijuana.
- Conditions
- Bipolar Disorder, Cannabis Use, Schizoaffective Disorder, Bipolar Type, Bipolar I Disorder
- Trial name
- NCT05064319
- Testing
- Gabapentin
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Medical University of South Carolina
Cannabis Use Disorder, Moderate, Cannabis Use Disorder, Severe
Psilocybin in the Treatment of Cannabis Use Disorder: A-Proof-of-Concept Study
Cannabis is the most commonly used psychoactive substance in Canada (Lowry \& Corsi, 2020). A sub-group of cannabis users develop a condition known as Cannabis Use Disorder (CUD), which is defined as a regular pattern of cannabis…
- Trial name
- PSI_CUD (NCT06225232)
- Testing
- Psilocybin combined with Psychotherapy
- Where
- Canada
- Volunteers
- 16 people
- Sponsor
- McMaster University
Depression - Major Depressive Disorder, Cannabis Use Disorder
Preliminary Efficacy Trial of a Digital Intervention for Depression and Cannabis Use
The purpose of this study is to examine the feasibility, acceptability, and preliminary efficacy of a digital intervention for co-occurring cannabis use and depression.
- Conditions
- Depression - Major Depressive Disorder, Cannabis Use Disorder, Mental Disorder
- Trial name
- NCT06878859
- Testing
- Amplification of Positivity - Cannabis Use (AMP-C)
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Massachusetts General Hospital
Cannabis Use Disorder, Major Depressive Disorder (MDD)
Pregnenolone for Cannabis Use Disorder and Depression
This is UG3 phase of a multi-site, milestone-driven UG3/UH3 research program evaluating pregnenolone for individuals with co-occurring cannabis use disorder (CUD) and major depressive disorder (MDD).
- Trial name
- PREG-CUD-MDD (NCT07685964)
- Testing
- Pregnenolone
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- University of Texas Southwestern Medical Center
Chronic Pain, Chronic Pain Syndrome
Outcomes Mandate National Integration With Cannabis as Medicine
This will be a multistate, multicenter clinical study to determine the efficacy and safety of medical cannabis for a wide variety of chronic medical conditions.
- Conditions
- Chronic Pain, Chronic Pain Syndrome, Chronic Pain Due to Injury, Chronic Pain Due to Trauma
- Trial name
- OMNI-Can (NCT03944447)
- Testing
- Cannabis, Medical, RYAH-Medtech Inhaler
- Where
- 17 sites in United States
- Volunteers
- 200,000 people, healthy volunteers welcome
- Sponsor
- OMNI Medical Services, LLC
Cannabis Use, Major Depressive Disorder
Extended Effects of Cannabis Abstinence on Clinical Symptoms and Cognition in Depression
The prevalence of major depressive disorder (MDD) is ~5.0%, and rates of co-occurring SUDs in these patients approach 40-50%. Specifically, rates of co-morbid cannabis use disorder (CUD) in patients with MDD are elevated 2-3 fold…
- Conditions
- Cannabis Use, Major Depressive Disorder, Cognitive Impairment
- Trial name
- NCT04935619
- Testing
- Contingency Reinforcement, Non-Contingency Reinforcement
- Where
- Canada
- Volunteers
- 52 people
- Sponsor
- Centre for Addiction and Mental Health
Cannabis Use Disorder, Major Depressive Disorder
Effects of Cannabis Abstinence on Symptoms and Cognition in Depression
The objective of this study is to assess the changes in symptoms and cognition that occur after a 28-day abstinence period in patients with comorbid Cannabis Use Disorder (CUD) and Major Depression (MDD).
- Conditions
- Cannabis Use Disorder, Major Depressive Disorder, Cognition
- Trial name
- NCT03624933
- Testing
- Weekly Behavioral Coaching Session, Contingency Management
- Where
- Canada
- Volunteers
- 19 people
- Sponsor
- Centre for Addiction and Mental Health
Cannabis Use Disorder
Deep Repetitive Transcranial Magnetic Stimulation for Cannabis Use Disorder
There is a credible basis for lateral prefrontal cortex and insula deep repetitive transcranial magnetic stimulation (dTMS) stimulation as a treatment for cannabis use disorder (CUD), but no studies to date have examined this.
- Trial name
- TRANS-CANN (NCT06114212)
- Testing
- dTMS stimulation via the H4 coil
- Where
- Canada
- Volunteers
- 12 people
- Sponsor
- St. Joseph's Healthcare Hamilton
Alcohol Abuse, Cannabis Abuse
Study Comparing Two Types of Psychotherapy for Treating Depression and Substance Abuse
The purpose of this study is to determine whether Integrated Cognitive Behavioral Therapy or Twelve Step Facilitation Therapy is most effective for treatment of dually diagnosed veterans with depressive and substance use…
- Conditions
- Alcohol Abuse, Cannabis Abuse, Major Depressive Disorder, Substance-Related Disorders
- Trial name
- NCT00108407
- Testing
- Integrated Cognitive Behavioral Therapy, Twelve Step Facilitation Therapy
- Where
- United States
- Sponsor
- US Department of Veterans Affairs